$CCXI WE OWN A COMPANY WITH EXCLUSIVE SALES FOR AVACOPAN USE FOR ANCA VASCULITIS 7YEARS IN USA 10YEARS EUROPE & JAPAN WITH 150-200k COST PER PATIENT'S YEAR. CCXI WILL HAVE 100% US PROFITS AND 20% WORLDWIDE. AVACOPAN IS IN PHASE 3 FOR 2 MORE DECEASE TREATMENTS WITH MILLION PATIENTS BE INTERESTED. US PATIENTS FOR ANCA ONLY 40k LETS SAY 13k FROM THEM CAN AFFORD AVACOPAN THATS 2.45billion PER YEAR WITH 165k COST PER PATIENT. OUR MARKET CAP IS ULTRA CHEAP WE WORTH AT LEAST 12-15billion. HOLD BUY AND PARTY🍾🍾
3
11
11 Likes